FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia With an Isocitrate Dehydrogenase-1 Mutation
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-18-3749
Full Text
Open PDFAbstract
Available in full text
Date
January 28, 2019
Authors
Publisher
American Association for Cancer Research (AACR)